Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
Posted on 10 Jul 2026
Hereditary risk stratification is central to timely prostate cancer detection, especially when disease presents at a young age. Although most malignancies arise from acquired mutations, an estimated 5% to 10% are caused by inherited variants that cluster in families. Identifying these variants can enable targeted surveillance and earlier intervention for at-risk relatives.
A research team at the University of British Columbia (UBC) has identified germline changes in cyclin-dependent kinase 12 (CDK12) as markers of a distinct hereditary subtype of prostate cancer. Although uncommon, the investigators report that these variants are associated with aggressive disease at relatively young ages. The findings also highlight a practical opportunity for laboratories, as current clinical technologies can already detect CDK12 mutations. The authors state that the results support adding CDK12 to standard hereditary prostate cancer testing panels.
Published in Cancer Discovery on July 2, 2026, the study analyzed genetic data from more than 4,500 individuals with aggressive prostate cancer and identified five unrelated men who carried inherited CDK12 mutations. All five had metastatic disease at diagnosis between ages 44 and 62. To verify causality, the researchers assessed tumors for a characteristic genetic “fingerprint” that appears when CDK12 is inactivated and found a signature pointing back to the gene. The project involved an international collaboration among UBC, BC Cancer, Vancouver Coastal Health Research Institute, and the University of Washington, with additional partners in Australia, the Netherlands, Spain, and Belgium.
Inherited CDK12 variants were detected in about one in every 1,000 people with aggressive prostate cancer, a frequency the team estimates could affect hundreds of families globally. The researchers also note a possible link to ovarian cancer: several patients had family histories of ovarian cancer, and one additional person with ovarian cancer carried an inherited CDK12 mutation with matching tumor changes. The study’s authors indicate that incorporating CDK12 into existing germline panels could be relatively straightforward, potentially enabling earlier identification of at-risk relatives and enhanced screening while curative options remain feasible.
Related Links
University of British Columbia
